GlassScriptPhysician profile
Rao S Botta
NPI 1275595381
$7,605.82
in general payments reported to CMS, 2019-2025
29 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $889 · 2020: $591 · 2021: $379 · 2022: $1,670 · 2023: $1,309 · 2024: $1,466 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,847 · Education: $205 · Consulting Fee: $24.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.83 |
| Education | $204.87 |
| Consulting Fee | $24.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,374.44 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $931.45 | 2019-2025 | Fasenra, Tezspire |
| Csl Behring | $899.83 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Regeneron Healthcare Solutions, INC. | $663.30 | 2019-2025 | Dupixent |
| Genzyme Corporation | $483.22 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $442.88 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Amgen INC. | $437.96 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $399.23 | 2019-2025 | |
| Pfizer INC. | $291.54 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $246.93 | 2022-2024 | |
| Genentech USA, INC. | $165.03 | 2019-2024 | Xolair |
| Abbvie INC. | $161.52 | 2021-2023 | Rinvoq |
| Bio Products Laboratory USA, INC. | $124.47 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $121.19 | 2019-2023 | |
| Pharming Healthcare, INC. | $118.84 | 2022-2025 | Ruconest |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $118.79 | 2022 | |
| Ionis Pharmaceuticals, INC. | $94.85 | 2025 | Dawnzera |
| Hospira, INC. | $94.70 | 2024-2025 | |
| Shire North American Group INC | $75.15 | 2019 | |
| Octapharma USA, INC. | $70.40 | 2023-2024 | Panzyga, Cutaquig |
| Adma Biomanufacturing LLC | $60.98 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.99 | 2021-2023 | Spiriva Respimat |
| Teva Pharmaceuticals USA, INC. | $37.45 | 2020-2021 | |
| Leo Pharma INC. | $37.20 | 2022-2025 | Adbry |
| Kaleo, INC. | $30.84 | 2020-2023 | Auvi-Q |
| Paratek Pharmaceuticals, INC. | $21.74 | 2025 | Xhance |
| Sunovion Pharmaceuticals INC. | $21.51 | 2019 | |
| Insmed, INC. | $19.23 | 2022 | |
| Hikma Pharmaceuticals USA | $15.16 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rao Botta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.